Literature DB >> 18096848

Structural factors influencing the efficacy of neuromuscular transmission.

Clarke R Slater1.   

Abstract

Neuromuscular junctions (NMJs) in different species share many features of structure and function. At the same time, important differences distinguish, for example, human NMJs from those in other species. An understanding of the biological context of the human NMJ helps in the interpretation of the effects of disease on the biophysical properties of neuromuscular transmission. Many NMJs consist of a number of spot-like synaptic regions 1-5 microm across. Usually only a few multimolecular "quanta" of transmitter are released from each presynaptic "bouton" by a single nerve impulse. The total number of quanta released from an NMJ is roughly proportional to its total area. For example, human NMJs are about 10-fold smaller than those in frogs and release about 20 quanta/impulse versus 100-200 in frog NMJ. Although human NMJs release relatively few quanta, the effect of the transmitter is amplified by the high density of voltage-gated sodium channels (Na(V)1.4) in the highly folded postsynaptic membrane. A genetic influence on NMJ size has recently been discovered in some patients with limb-girdle myasthenia (LGM). Mutations of the gene encoding Dok-7, an essential component of the agrin-muscle-specific kinase pathway that controls postsynaptic differentiation at the mammalian NMJ, results in impaired transmission because the NMJs are abnormally small and have reduced folding but have a normal local density of normal acetylcholine receptors. This condition emphasizes the importance of structural features in achieving reliability of neuromuscular transmission.

Entities:  

Mesh:

Year:  2007        PMID: 18096848     DOI: 10.1196/annals.1405.003

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

1.  Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.

Authors:  Grace M McMacken; Sally Spendiff; Roger G Whittaker; Emily O'Connor; Rachel M Howarth; Veronika Boczonadi; Rita Horvath; Clarke R Slater; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

Review 2.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

3.  Live imaging of bulk endocytosis in frog motor nerve terminals using FM dyes.

Authors:  Michael A Gaffield; Christin F Romberg; William J Betz
Journal:  J Neurophysiol       Date:  2011-05-04       Impact factor: 2.714

Review 4.  Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles.

Authors:  Alessandro Serra; Robert L Ruff; Richard John Leigh
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

5.  Effects of electrical stimulation on neuromuscular junction morphology in the aging rat tongue.

Authors:  Aaron M Johnson; Nadine P Connor
Journal:  Muscle Nerve       Date:  2011-02       Impact factor: 3.217

6.  Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome.

Authors:  W David Arnold; Daniel H Feldman; Sandra Ramirez; Liuyuan He; Darine Kassar; Adam Quick; Tara L Klassen; Marian Lara; Joanna Nguyen; John T Kissel; Christoph Lossin; Ricardo A Maselli
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

7.  Cell surface complement regulators moderate experimental myasthenia gravis pathology.

Authors:  Linda L Kusner; Jose A Halperin; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2012-10-05       Impact factor: 3.217

8.  Aberrant development of neuromuscular junctions in glycosylation-defective Large(myd) mice.

Authors:  Ruth Herbst; Thomas Iskratsch; Ewald Unger; Reginald E Bittner
Journal:  Neuromuscul Disord       Date:  2009-04-05       Impact factor: 4.296

Review 9.  Are unreliable release mechanisms conserved from NMJ to CNS?

Authors:  Tyler B Tarr; Markus Dittrich; Stephen D Meriney
Journal:  Trends Neurosci       Date:  2012-10-25       Impact factor: 13.837

10.  How myasthenia gravis alters the safety factor for neuromuscular transmission.

Authors:  Robert L Ruff; Vanda A Lennon
Journal:  J Neuroimmunol       Date:  2008-07-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.